Your shopping cart is empty

Subscriber login

Advanced Search

Home
Books
Conferences
DVDs
Newsletters
Form 483s
Pharma Quality Advisor
Webinar Training Pass
White Papers
Advertising/Sponsorships
About Us

Check out our free and informative ezines and sign up now

Home > Newsletters > Drug Industry Daily > Genentech Gets Untitled Letter for Misleading Claims in Oncology Drug Promo

Drug Industry Daily

Oct. 15, 2012 | Vol. 11 No. 202

Genentech Gets Untitled Letter for Misleading Claims in Oncology Drug Promo

The FDA has issued an untitled letter to Genentech for educational aids aimed at healthcare professionals that overstate the efficacy and minimize the risks of its cancer drug Tarceva.

This article is viewable by subscribers only. To view this article, please select an option below.

Subscribe
Print This Page
Email This Article
RSS
Free Trial
Archives
Sample PDF

Sigma-Tau, Validus Get Untitled Letters for Marketing Claims Alcon Sales Aid for Patanase Draws Untitled Letter for Overstating Efficacy Genentech Gets Untitled Letter for Claims in Oncology Drug Promo Eli Lilly Ad for Alzheimer’s PET Drug Draws Untitled Letter for Misleading Imagery

Home
Advertising/Sponsorships
About Us
Contact Us
Site Map
Privacy Policy

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.